Atossa Therapeutics (ATOS) Free Cash Flow (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Free Cash Flow of -$8.9 million for Q1 2026, down 48.94% year-over-year from -$17.4 million in Q1 2025, and up 16.2% quarter-over-quarter from -$10.6 million in Q4 2025.
Atossa Therapeutics (ATOS) Free Cash Flow (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Free Cash Flow for 16 consecutive years, with -$8.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 48.94% year-over-year to -$8.9 million; the TTM figure through Mar 2026 stood at -$32.7 million (down 46.71% YoY), while the FY2025 annual figure was -$29.8 million, down 41.68% from the prior year.
- Free Cash Flow improved to -$8.9 million in Q1 2026 per ATOS's latest filing, from -$10.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$3.9 million in Q4 2023 and bottomed at -$10.6 million in Q4 2025.
- Historically, Free Cash Flow has averaged -$6.0 million across 5 years, with a median of -$6.0 million in 2022.
- Annual changes were most pronounced in 2022 — Free Cash Flow plunged 95.18% — and 2024, when it jumped 33.1%.
- Atossa Therapeutics' Free Cash Flow stood at -$4.0 million in 2022, then increased by 1.64% to -$3.9 million in 2023, then sank by 80.81% to -$7.0 million in 2024, then sank by 50.88% to -$10.6 million in 2025, then rose by 16.2% to -$8.9 million in 2026.
- Business Quant data shows ATOS's Free Cash Flow at -$8.9 million in Q1 2026, -$10.6 million in Q4 2025, and -$6.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | -9.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.63 Mn |
| Jun 30, 2026 | -9.63 Mn |
| Mar 31, 2026 | -8.89 Mn |
| Mar 31, 2026 | -8.89 Mn |
| Dec 31, 2025 | -10.61 Mn |
| Dec 31, 2025 | -10.61 Mn |
| Sep 30, 2025 | -6.01 Mn |
| Sep 30, 2025 | -6.01 Mn |
| Jun 30, 2025 | -7.24 Mn |
| Jun 30, 2025 | -7.24 Mn |
| Mar 31, 2025 | -5.97 Mn |
| Mar 31, 2025 | -5.97 Mn |
| Dec 31, 2024 | -7.03 Mn |
| Dec 31, 2024 | -7.03 Mn |
| Sep 30, 2024 | -4.78 Mn |
| Sep 30, 2024 | -4.78 Mn |
| Jun 30, 2024 | -4.54 Mn |
| Jun 30, 2024 | -4.54 Mn |
| Mar 31, 2024 | -4.70 Mn |
| Mar 31, 2024 | -4.70 Mn |